ATRYE Stock Overview
Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Atrys Health, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €6.08 |
| 52 Week High | €6.82 |
| 52 Week Low | €5.74 |
| Beta | 0.45 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -10.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| ATRYE | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.0% | 2.5% |
| 1Y | n/a | -29.8% | 5.8% |
Return vs Industry: Insufficient data to determine how ATRYE performed against the UK Healthcare industry.
Return vs Market: Insufficient data to determine how ATRYE performed against the UK Market.
Price Volatility
| ATRYE volatility | |
|---|---|
| ATRYE Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ATRYE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ATRYE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,173 | Isabel Lozano Fernandez | www.atryshealth.com |
Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
Atrys Health, S.A. Fundamentals Summary
| ATRYE fundamental statistics | |
|---|---|
| Market cap | €371.68m |
| Earnings (TTM) | -€23.21m |
| Revenue (TTM) | €191.83m |
1.9x
P/S Ratio-16.0x
P/E RatioIs ATRYE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATRYE income statement (TTM) | |
|---|---|
| Revenue | €191.83m |
| Cost of Revenue | €121.58m |
| Gross Profit | €70.26m |
| Other Expenses | €93.47m |
| Earnings | -€23.21m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 36.62% |
| Net Profit Margin | -12.10% |
| Debt/Equity Ratio | 59.8% |
How did ATRYE perform over the long term?
See historical performance and comparison